GT Biopharma to Participate in the 38th Annual Roth Conference
MWN-AI** Summary
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company, has announced its participation in the 38th Annual Roth Conference, scheduled for March 22-24, 2026, at Laguna Niguel, California. The company’s Executive Chairman and CEO, Michael Breen, will present on March 24th at 1:30 PM PDT. The conference will provide an opportunity for one-on-one meetings, allowing potential investors to engage directly with the company representatives.
GT Biopharma is focused on developing therapeutics that leverage its proprietary TriKE® (TriTANK-Engager) platform, aimed at enhancing the natural killer (NK) cell response of the immune system against cancer. This innovative approach harnesses the body’s own defenses to improve anti-cancer efficacy. With an exclusive license agreement with the University of Minnesota, GT Biopharma is positioned to further advance its TriKE® technology for therapeutic applications.
The company is noted for its commitment to advancing immunotherapy treatments that could transform cancer care. However, it acknowledges that forward-looking statements about its future prospects carry inherent risks and uncertainties, and actual results may significantly deviate from these projections. Investors are urged to review GT Biopharma’s recent reports filed with the Securities and Exchange Commission for a comprehensive understanding of potential risks associated with the business.
For more details about GT Biopharma and its innovative development programs, stakeholders can visit its website. The engagement at the Roth Conference marks an important networking and exposure opportunity for the company, as it seeks to attract investment and advance its clinical objectives in the competitive biopharmaceutical landscape.
MWN-AI** Analysis
As GT Biopharma, Inc. prepares to participate in the 38th Annual Roth Conference, investors should consider the implications of this event for the company's positioning within the biopharmaceutical sector. The conference provides a significant platform for GT Biopharma to showcase its proprietary TriKE® technology, which has the potential to transform immuno-oncology therapies by leveraging natural killer (NK) cells to target and eradicate cancer cells effectively.
Investment in GT Biopharma might appeal to those seeking exposure to innovative biopharmaceutical solutions. As the company is in a clinical stage of development, the upcoming presentation by Michael Breen, the Executive Chairman and CEO, will likely focus on the progress of their therapies, clinical trial outcomes, and the commercialization strategy, key aspects that can influence investor sentiment and stock performance.
Given the inherent volatility in biotech investments, potential investors should carefully assess the risks associated with the company's forward-looking statements about their clinical advancements and market potential. The company's reliance on the exclusive license from the University of Minnesota is a key factor, as successful development hinges on maintaining this collaboration and delivering on clinical trial milestones.
Moreover, the scheduled one-on-one investor meetings at the conference may help GT Biopharma secure interest from institutional investors, signaling confidence in the company's trajectory. As the market continues to shift toward precision medicine and immuno-oncology, monitoring GT Biopharma's innovations and performance after the conference will be crucial.
In summary, while GT Biopharma's innovative TriKE® platform offers compelling growth potential, investors should weigh the associated risks, particularly in the context of clinical outcomes and market acceptance. Engaging with the company during the Roth Conference might provide deeper insights useful for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN FRANCISCO, CALIFORNIA, March 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will participate in the 38th Annual Roth Conference being held March 22-24, 2026 in Laguna Niguel, CA.
38th Annual Roth Conference
Format: Presentation and 1x1 investor meetings
Presentation Date: Tuesday, March 24th, 2026
Time: 1:30 PM PDT
The Company will be available for one-on-one meetings at the conference. If interested, please contact your Roth representative.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
LinkedIn |Facebook |X |Instagram | YouTube
FAQ**
What new developments or advancements in the TriKE® platform does GT Biopharma Inc. GTBP plan to highlight during the 38th Annual Roth Conference?
How does GT Biopharma Inc. GTBP's exclusive agreement with the University of Minnesota enhance its competitive edge in the immuno-oncology market?
What key metrics or milestones will GT Biopharma Inc. GTBP focus on during its one-on-one meetings at the conference to attract potential investors?
How are the forward-looking statements in GT Biopharma Inc. GTBP's press release relevant to the company's strategic plans and stakeholder interests for the future?
**MWN-AI FAQ is based on asking OpenAI questions about GT Biopharma Inc. (NASDAQ: GTBP).
NASDAQ: GTBP
GTBP Trading
37.97% G/L:
$0.44 Last:
8,878,967 Volume:
$0.374 Open:
